- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial primary completion date: INI-PD: Intranasal Insulin in Parkinson's Disease (clinicaltrials.gov) - Oct 4, 2022
P2, N=30, Recruiting,
Trial completion date: Jan 2023 --> Jul 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL) (clinicaltrials.gov) - Aug 18, 2022
P1, N=40, Active, not recruiting,
N=60 --> 80 Recruiting --> Active, not recruiting | Trial completion date: Feb 2022 --> Dec 2023 | Trial primary completion date: Feb 2022 --> Dec 2022
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Microneedling with autologous platelet-rich plasma verses microneedling with topical insulin in the treatment of post-acne atrophic scars: a simultaneous split-face comparative study () - Aug 16, 2022 - Abstract #ESDR2022ESDR_658;
Exclusion criteria included presence of active acne and/or infections over face, pregnancy or lactation, on isotretinoin, and history of keloidal tendency, bleeding disorders and deranged blood sugar levels...On right side of the face, 1-2ml TI (Human actrapid insulin 40IU/ml® solution) was applied, while on left side 1-2ml autologous PRP was applied...Both, TI and PRP, combined with microneedling may achieve comparable improvement with advantageous safety profile in PAS. However, readily accessibility, low cost, and non-invasive nature merits the use of TI over PRP
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial initiation date, Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Jul 14, 2022
P2/3, N=30, Not yet recruiting,
The MemAID trial provides proof-of-concept for preliminary safety and efficacy and supports future evaluation of INI role to treat T2DM and age-related functional decline. Initiation date: Jun 2022 --> Oct 2022 | Trial primary completion date: Aug 2022 --> Dec 2022
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial initiation date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Apr 4, 2022
P2/3, N=30, Not yet recruiting,
N=40 --> 60 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Initiation date: Mar 2022 --> Jun 2022
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
PK/PD data, Journal: Variability in insulin pharmacokinetics following high-dose insulin therapy. (Pubmed Central) - Mar 31, 2022
A man ingesting diltiazem received HDI for approximately 60 h (maximum dose 10 U/kg/h) and supplemental intravenous dextrose for 44 h post-HDI...A man ingesting propranolol received HDI for approximately 12 h (maximum dose 1.5 U/kg/h) and supplemental intravenous dextrose for 4 h post-HDI...This pharmacokinetic variability impacts on the severity and duration of treatable hypoglycemia post-HDI. Analytical factors impacting on the measured plasma insulin concentrations include appropriate sample dilution and differing analytical specificity for the type of insulin.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Journal: Synthesis and Identification of Biologically Active Mono-Labelled FITC-Insulin Conjugate. (Pubmed Central) - Mar 24, 2022
Human insulin (Actrapid®) was labelled with fluorescein isothiocyanate (FITC) and the synthesised conjugate identified using reverse phase high performance liquid chromatography (RP-HPLC) on a C18 column and a gradient method with mobile phase A containing 0.1% trifluoroacetic acid (TFA) in Millipore water and mobile phase B containing 90% Acetonitrile, 10% Millipore water and 0.1% TFA...No significant difference in the cellular response was observed for monoB1 produced in-house compared to native insulin. Therefore mono-labelled FITC-insulin at the B1 position showed similar biological activity as native insulin and can potentially be used for future biomedical applications.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial primary completion date: INI-PD: Intranasal Insulin in Parkinson's Disease (clinicaltrials.gov) - Mar 15, 2022
P2, N=30, Recruiting,
Therefore mono-labelled FITC-insulin at the B1 position showed similar biological activity as native insulin and can potentially be used for future biomedical applications. Trial completion date: Apr 2022 --> Jan 2023 | Trial primary completion date: Feb 2022 --> Dec 2022
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date: Tight Glycemic Control With Intensive Insulin Therapy in PICU (clinicaltrials.gov) - Mar 10, 2022
P2, N=700, Active, not recruiting,
Trial completion date: Apr 2022 --> Jan 2023 | Trial primary completion date: Feb 2022 --> Dec 2022 Trial completion date: Jun 2021 --> Jun 2023
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Journal: Engineering of a Biologically Active Insulin Dimer. (Pubmed Central) - Jan 26, 2022
In in vivo insulin tolerance tests, the dimer was equipotent to Actrapid insulin and possessed a sustained duration of action greater than that of Actrapid and Glargine...More importantly, our analogue was produced in quantitative yield from a monomeric thiol insulin scaffold. Our results suggest that this dimer has significant potential to address the clinical needs in the treatment of diabetes.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date: INI-PD: Intranasal Insulin in Parkinson's Disease (clinicaltrials.gov) - Sep 28, 2021
P2, N=30, Recruiting,
The study demonstrated bioequivalence between BAX-HI and NOVO-HI in terms of PK and PD characteristics in healthy males. Trial completion date: Jan 2022 --> Apr 2022
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Journal: Selection Experiments in the Sea: What Can Experimental Evolution Tell Us About How Marine Life Will Respond to Climate Change? (Pubmed Central) - Sep 26, 2021
AbstractRapid evolution may provide a buffer against extinction risk for some species threatened by climate change; however, the capacity to evolve rapidly enough to keep pace with changing environments is unknown for most taxa...The application of experimental evolution in this context has grown dramatically in the past decade, shedding light on the capacity for evolution, associated trade-offs, and the genetic architecture of stress-tolerance traits. Our goal is to highlight the utility of this approach for investigating potential responses to climate change and point a way forward for future studies.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, NN1213 / Novo Nordisk
Phase classification: Memory Aid by Intranasal Insulin in Diabetes (MemAID) (clinicaltrials.gov) - Sep 17, 2021
P2, N=289, Completed,
Our goal is to highlight the utility of this approach for investigating potential responses to climate change and point a way forward for future studies. Phase classification: P2/3 --> P2
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial suspension, Trial primary completion date: Intranasal Insulin in Frontotemporal Dementia (FTD) (clinicaltrials.gov) - Aug 26, 2021
P2, N=12, Suspended,
Phase classification: P2/3 --> P2 Trial completion date: Sep 2021 --> Apr 2023 | Recruiting --> Suspended | Trial primary completion date: Jul 2021 --> Dec 2022
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Enrollment open, Trial completion date, Trial primary completion date: Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL) (clinicaltrials.gov) - Jul 26, 2021
P1, N=40, Recruiting,
Trial completion date: Sep 2021 --> Apr 2023 | Recruiting --> Suspended | Trial primary completion date: Jul 2021 --> Dec 2022 Not yet recruiting --> Recruiting | Trial completion date: Sep 2021 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial primary completion date: Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders (clinicaltrials.gov) - May 9, 2021
P2, N=40, Recruiting,
Therefore, for pregnant women with gestational diabetes, who require insulin therapy, IDet would be an ideal basal insulin being worthy of promotion in clinical settings. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Intranasal Insulin for the Treatment of HAND (clinicaltrials.gov) - Mar 2, 2021
P1/2, N=21, Terminated,
N=40 --> 21 | Trial completion date: Jul 2021 --> Oct 2020 | Recruiting --> Terminated | Trial primary completion date: Jul 2021 --> May 2020; On 3/15/2020 study visits were suspended due to COVID-19 pandemic. With safety concerns surrounding COVID-19 and difficulty recruiting, the investigators decided to close enrollment 10/16/2020 after interim data were reviewed by the DSMB and NIH.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial termination, Trial primary completion date: Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD (clinicaltrials.gov) - Oct 26, 2020
P4, N=40, Terminated,
The approach taken may be of wider utility in characterizing injectables for subcutaneous administration. Trial completion date: Dec 2019 --> Sep 2020 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Sep 2020; The study required more participants than anticipated for statistical significance.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial primary completion date: Intranasal Insulin in Frontotemporal Dementia (FTD) (clinicaltrials.gov) - Sep 17, 2020
P2, N=12, Recruiting,
Trial completion date: Dec 2019 --> Sep 2020 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Sep 2020; The study required more participants than anticipated for statistical significance. Trial completion date: Nov 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Jul 2021
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Biomarker, Enrollment change, Trial completion date, Trial termination: Neuro Biomarkers of Smoking Behavior (clinicaltrials.gov) - Sep 11, 2020
P2, N=4, Terminated,
Trial completion date: Nov 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Jul 2021 N=800 --> 4 | Trial completion date: Sep 2020 --> Sep 2019 | Recruiting --> Terminated; Different study initiation
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial termination, Surgery, Bariatric surgery: Management of Type 2 Diabetes After Gastric Bypass Surgery (clinicaltrials.gov) - Aug 21, 2020
P=N/A, N=50, Terminated,
N=800 --> 4 | Trial completion date: Sep 2020 --> Sep 2019 | Recruiting --> Terminated; Different study initiation Completed --> Terminated; Data were published that superseded this study.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, NN1213 / Novo Nordisk
Trial completion: Memory Aid by Intranasal Insulin in Diabetes (MemAID) (clinicaltrials.gov) - Jun 19, 2020
P2/3, N=244, Completed,
Completed --> Terminated; Data were published that superseded this study. Active, not recruiting --> Completed
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, NN1213 / Novo Nordisk
Enrollment closed: Memory Aid by Intranasal Insulin in Diabetes (MemAID) (clinicaltrials.gov) - Apr 27, 2020
P2/3, N=289, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Effect of Intranasal Insulin on Cognitive Processes and Appetite (clinicaltrials.gov) - May 1, 2019
P=N/A, N=64, Completed,
Phase classification: P=N/A --> P2 Recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Jan 2019 --> Apr 2019
|
